In terms of responses to anti-PD-1/PD-L1, biomarkers such as tumor mutational load, PD-L1 expression, and intra-tumoral cytotoxic CD8+ T-cell infiltrates have been proposed, but further investigations are necessary to select the most suitable [5]. The gene discussed is CD274; the disease is neoplasm.